QIPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quipt Home Medical Corp (QIPT) is not a good buy for a beginner, long-term investor at this time. The stock is undergoing an acquisition process that will result in delisting, reducing market transparency and liquidity. While the acquisition may enhance competitiveness, the lack of future trading opportunities and the current overbought technical indicators make it unsuitable for investment under the given scenario.
The stock is overbought with an RSI of 80.157, and the MACD histogram is negative at -0.00367, indicating a potential bearish divergence. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance is at 3.649, and support is at 3.611, with the stock trading near its pivot point of 3.63.
The acquisition by Kingswood Capital and Forager Capital is expected to enhance Quipt's competitiveness in the U.S. healthcare market and expand its service offerings.
The acquisition will result in delisting from major exchanges, reducing market transparency and liquidity. Additionally, the stock is overbought, and financial performance shows declining net income and EPS.
In Q1 2026, revenue increased by 31.96% YoY to $80.996M, but net income dropped by 2.86% YoY to -$1.053M, and EPS decreased by 33.33% YoY to -0.02. Gross margin improved to 56.38%, up 6.10% YoY.
Canaccord analyst Richard Close raised the price target to $3.65 from $2.30 and maintained a Hold rating, reflecting the acquisition price and limited upside potential.
